{"gene":"HAVCR2","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2005,"finding":"Galectin-9 was identified as a functional ligand for TIM-3. Galectin-9 binding to TIM-3 induced intracellular calcium flux, cell aggregation, and selective death of TH1 cells in vitro; in vivo administration caused loss of IFN-γ-producing cells and suppression of TH1 autoimmunity in a TIM-3-dependent manner.","method":"In vitro calcium flux assay, cell aggregation/death assays with Tim-3-expressing T cells, in vivo galectin-9 administration in mouse autoimmunity model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal in vitro assays plus in vivo validation, replicated across subsequent studies; ligand-receptor interaction established functionally","pmids":["16286920"],"is_preprint":false},{"year":2013,"finding":"NEGATIVE FINDING: Extensive binding studies did not yield evidence for specific interaction between galectin-9 and human or murine TIM-3, and galectin-9 did not affect activation of human T cells. Anti-TIM-3 antibodies failed to increase anti-HIV T cell responses in vitro.","method":"T cell activation assays, extensive binding studies (human and murine TIM-3 vs. galectin-9), HIV patient T cell functional assays","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal binding and functional assays in a single lab; contradicts PMID 16286920 but uses human system specifically","pmids":["23555261"],"is_preprint":false},{"year":2015,"finding":"TIM-3 enhances FcεRI-proximal signaling in mast cells by acting at a receptor-proximal point to augment Lyn kinase-dependent pathways, thereby modulating both immediate-phase degranulation and late-phase cytokine production downstream of FcεRI ligation.","method":"Gain- and loss-of-function approaches in mast cells, signaling pathway analysis (Lyn kinase), degranulation and cytokine production assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with defined signaling readout, multiple orthogonal assays in a single rigorous study","pmids":["26598760"],"is_preprint":false},{"year":2018,"finding":"Germline missense mutations in HAVCR2 (p.Tyr82Cys and p.Ile97Met) cause protein misfolding and abolish TIM-3 plasma membrane expression, leading to persistent immune activation and increased production of TNF-α and IL-1β, promoting hemophagocytic lymphohistiocytosis (HLH) and subcutaneous panniculitis-like T cell lymphoma (SPTCL).","method":"Genetic sequencing, protein expression analysis (Western blot/surface expression), cytokine quantification in patient samples and cell models","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mutations with defined molecular (protein misfolding, loss of surface expression) and cellular (cytokine hypersecretion) phenotypes in human patient cohort with functional validation","pmids":["30374066"],"is_preprint":false},{"year":2019,"finding":"Phosphatidylserine (PtdSer) engagement promotes phosphorylation of TIM-3 on NK cells, which then competes with PI3K p110 subunit to bind the p85 regulatory subunit, thereby inhibiting downstream Akt/mTORC1 signaling and suppressing NK cell cytokine secretion and cytotoxic activity in hepatocellular carcinoma.","method":"Phosphorylation assays, competitive binding of TIM-3 vs. PI3K p110 for p85, Akt/mTORC1 pathway analysis, NK cell functional assays, in vivo HCC tumor model with TIM-3 blockade","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — defined biochemical mechanism (TIM-3 phosphorylation, competitive p85 binding) with downstream signaling validation and in vivo confirmation in a single rigorous study","pmids":["31848194"],"is_preprint":false},{"year":2021,"finding":"TIM-3 on dendritic cells (DCs) restrains anti-tumor immunity by preventing NLRP3 inflammasome activation; loss of TIM-3 in DCs leads to increased reactive oxygen species accumulation, NLRP3 inflammasome activation, and IL-1β/IL-18-dependent promotion of CD8+ effector and stem-like T cells. TIM-3 deletion in DCs—but not in CD4+ or CD8+ T cells—was responsible for the anti-tumor effect.","method":"Conditional knockout of TIM-3 in DCs, CD4+ T cells, and CD8+ T cells (cell-type-specific genetic epistasis); single-cell RNA sequencing; ROS measurement; inflammasome activity assays; IL-1β/IL-18 blockade experiments; tumor growth assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — conditional cell-type-specific KO with genetic epistasis, multiple orthogonal mechanistic assays, scRNA-seq, and pharmacologic rescue in a rigorous single study","pmids":["34108686"],"is_preprint":false},{"year":2021,"finding":"TIM-3 binding to phosphatidylserine (PS) promotes NF-κB signaling and IL-2 secretion downstream of TCR stimulation in Jurkat T cells; this co-stimulatory activity is blocked by mutating the PS-binding site or by occluding it with antibody. TIM-3 signaling also alters CD28 phosphorylation.","method":"PS-binding site mutagenesis, NF-κB reporter assays, IL-2 ELISA, CD28 phosphorylation analysis, antibody blockade of PS-binding site in Jurkat cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with signaling assays and antibody blockade, multiple orthogonal methods in one study establishing PS as functional ligand for TIM-3 signaling","pmids":["34435619"],"is_preprint":false},{"year":2021,"finding":"TIM-3 promotes ubiquitination and proteasomal degradation of NF90 (a virus sensor) in macrophages during VSV infection by recruiting E3 ubiquitin ligase TRIM47 to the zinc finger domain of NF90, initiating K48-linked ubiquitination at Lys297, thereby suppressing stress granule formation and antiviral innate immunity.","method":"Co-immunoprecipitation, ubiquitination assays (K48-linkage), domain mapping, Tim-3 conditional inactivation, downstream stress granule marker analysis (G3BP1, TIA-1), eIF2α/PKR phosphorylation assays, in vivo VSV challenge","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — biochemical mechanism defined at residue level (Lys297) with Co-IP, ubiquitination assays, multiple downstream readouts, and in vivo validation in a single rigorous study","pmids":["34110282"],"is_preprint":false},{"year":2022,"finding":"TIM-3 on dendritic cells (APCs) mediates trogocytosis—transfer of membrane fragments from APCs to T cells. TIM-3 blockade on Tim-3+ APCs disrupted phosphatidylserine-dependent trogocytosis of activated CD8+ T cells and PD-1+Tim-3+ TILs. Trogocytosed CD8+ T cells presented tumor peptide-MHC complexes and became targets of fratricide killing, which was reversed by TIM-3 blockade. Conditional deletion of TIM-3 in DCs but not CD8+ T cells impeded trogocytosis in vivo.","method":"Human melanoma TIL analysis, PS-blocking experiments, DC-specific TIM-3 conditional deletion in vivo, two melanoma mouse models, functional assays for trogocytosis and fratricide T cell killing","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — DC-specific conditional KO with defined cellular mechanism, PS-dependent trogocytosis validated in multiple models and patient samples, orthogonal methods","pmids":["35316223"],"is_preprint":false},{"year":2022,"finding":"Bat3, an adaptor protein that binds the cytoplasmic tail of TIM-3, acts as an endogenous regulator of DC function. Loss of Bat3 in DCs leads to hyperactive unfolded protein response and redirects acetyl-CoA toward increased cell-intrinsic steroidogenesis, which suppresses T cell responses in a paracrine manner; this skews the immune response toward regulatory T cells and exhausted CD8+ TILs.","method":"Bat3 conditional deletion in DCs, autoimmunity (EAE) and cancer (MC38-OVA) mouse models, steroidogenesis assays, acetyl-CoA metabolic analysis, T cell compartment phenotyping","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined metabolic mechanism, multiple in vivo disease models, orthogonal metabolic and immunologic assays in a single rigorous study","pmids":["35275752"],"is_preprint":false},{"year":2024,"finding":"TIM-3 is palmitoylated by the palmitoyltransferase DHHC9 at cysteine 296 (Cys296). Palmitoylation stabilizes TIM-3 by preventing its binding to E3 ubiquitin ligase HRD1, thereby suppressing TIM-3 polyubiquitination and degradation. DHHC9 knockdown attenuated CAR-T cell exhaustion, and a peptidic inhibitor of TIM-3 palmitoylation accelerated TIM-3 degradation and enhanced antitumor immunity.","method":"Palmitoylation assays, site-directed mutagenesis (Cys296), Co-IP with HRD1, ubiquitination assays, DHHC9 knockdown, CAR-T cell exhaustion assays, peptidic inhibitor experiments","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — palmitoylation at specific residue identified with mutagenesis, biochemical interaction with HRD1 shown by Co-IP, ubiquitination rescue experiments, and functional validation in CAR-T cells","pmids":["39546589"],"is_preprint":false},{"year":2025,"finding":"TGFβ signaling induces TIM-3 expression in microglia. TIM-3 in turn interacts with SMAD2 and TGFBR2 through its C-terminal tail, enhancing TGFβ signaling by promoting TGFBR-mediated SMAD2 phosphorylation; this maintains microglial homeostasis. Microglial-specific deletion of Havcr2 increases phagocytic activity and shifts microglia toward a neurodegenerative (MGnD/DAM) phenotype, ameliorating amyloid-β pathology and cognitive impairment in 5×FAD mice.","method":"Co-immunoprecipitation (TIM-3 with SMAD2 and TGFBR2), SMAD2 phosphorylation assays, microglia-specific conditional Havcr2 knockout (Cre-lox), 5×FAD Alzheimer's model behavioral and pathology analyses, single-nucleus and single-cell RNA sequencing","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP defining interaction partners, phosphorylation assays, cell-type-specific conditional KO, in vivo disease model rescue, and transcriptomic validation constitute multiple orthogonal rigorous methods","pmids":["40205047"],"is_preprint":false},{"year":2021,"finding":"In CD4+ T cells during sepsis, HMGB1 binds to TIM-3 and this interaction inhibits the NF-κB signaling pathway in TIM-3+ CD4+ T cells, contributing to sepsis-induced immunosuppression. Conditional or systemic deletion of Tim-3 reduced sepsis mortality.","method":"Colocalization analysis of HMGB1 and TIM-3 on CD4+ T cells, NF-κB signaling pathway analysis, conditional Tim-3 deletion in CD4+ T cells, in vivo sepsis mouse model mortality assay","journal":"Molecular therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — colocalization plus conditional KO with pathway analysis, but binding mechanism based on colocalization rather than direct biochemical interaction assay","pmids":["34933101"],"is_preprint":false},{"year":2019,"finding":"Tim-3 signaling in Vγ9Vδ2 T cells reduces perforin and granzyme B expression through an ERK1/2-dependent pathway, thereby suppressing cytotoxic killing of colon cancer cells.","method":"Tim-3 signaling activation experiments, perforin/granzyme B expression analysis, ERK1/2 pathway inhibition, cytotoxicity assays against colon cancer cells","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — defined signaling pathway (ERK1/2) linking TIM-3 to effector molecule expression with functional cytotoxicity readout, single lab","pmids":["31726050"],"is_preprint":false},{"year":2022,"finding":"In glioblastoma cells, TIM-3 regulates IL-6 expression through NF-κB activation; cell-intrinsic TIM-3/IL-6 signaling induces macrophage migration and M2/anti-inflammatory polarization. Blocking IL-6 receptor with tocilizumab suppressed these effects and repressed GBM tumorigenicity in vivo.","method":"TIM-3 overexpression/knockdown in glioma cells, NF-κB pathway analysis, IL-6 quantification, macrophage co-culture migration and polarization assays, in vivo GBM tumor model with tocilizumab treatment","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — gain- and loss-of-function with defined NF-κB/IL-6 mechanism, macrophage functional readout, and in vivo pharmacologic rescue; single lab","pmids":["36325060"],"is_preprint":false},{"year":2022,"finding":"Tim-3 expressed in macrophages suppresses neutrophil necroptosis during colitis by inhibiting the TLR4/NF-κB pathway; macrophage-specific Tim-3 knockout increased ROS-driven neutrophil necroptosis and colitis severity. RIP1/RIP3 or ROS inhibition reversed the inflammation in Tim-3 KO mice.","method":"Macrophage-specific Tim-3 conditional knockout mice, DSS-induced colitis model, TLR4/NF-κB pathway analysis, RIP1/RIP3 and ROS pharmacologic inhibitors, neutrophil necroptosis assays","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific conditional KO with defined TLR4/NF-κB pathway mechanism, pharmacologic rescue, and multiple readouts; single lab","pmids":["38330550"],"is_preprint":false},{"year":2022,"finding":"Tim-3 suppresses MHC-II expression in macrophages via the STAT1/CIITA pathway, thereby inhibiting MHC-II-mediated autoantigen presentation and CD4+ T cell activation. Overexpression or blockade of Tim-3 signaling altered MHC-II expression and clinical outcomes in EAE mice.","method":"Tim-3 overexpression/blockade in EAE mouse model, STAT1/CIITA pathway analysis, MHC-II expression assays, CD4+ T cell activation assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — defined STAT1/CIITA pathway mechanism with in vivo gain- and loss-of-function and functional antigen presentation readout; single lab","pmids":["35095844"],"is_preprint":false},{"year":2021,"finding":"Tim-3 suppresses Th17-mediated autoimmune hepatitis through the p38/MKP-1 pathway; blocking Tim-3 increased Th17 cell frequency and p38/MKP-1 and p-JNK activation, elevating IL-17A and liver damage.","method":"Anti-Tim-3 blockade in Con A-induced mouse AIH model, p38 inhibitor experiments, MKP-1 and IL-17A quantification, liver histology/enzyme assays","journal":"FEBS open bio","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway defined by pharmacologic inhibition and antibody blockade alone, single lab, no direct biochemical mechanism linking TIM-3 to p38/MKP-1","pmids":["33728805"],"is_preprint":false},{"year":2016,"finding":"T-bet transcription factor, induced in monocyte/macrophages by HCV core protein via gC1qR interaction and the JNK signaling pathway, drives Tim-3 expression; silencing T-bet decreases Tim-3 expression, enhances IL-12 secretion and STAT1 phosphorylation in macrophages.","method":"T-bet knockdown, HCV core protein stimulation of primary macrophages and THP-1 cells, JNK inhibitor (SP600125), T-bet/Tim-3 correlation analysis, IL-12/STAT1 phosphorylation assays","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — T-bet identified as upstream transcriptional regulator of TIM-3 using siRNA knockdown plus pathway inhibitor with downstream functional readouts; single lab","pmids":["27809352"],"is_preprint":false},{"year":2020,"finding":"NEGATIVE FINDING: TIM-3 and CEACAM1 do not interact in cis or in trans. Extensive binding studies found no evidence of direct TIM-3–CEACAM1 interaction, and CEACAM1-mediated inhibition did not involve TIM-3. However, cytoplasmic sequences derived from TIM-3 independently induced inhibitory signaling in a human T cell reporter system.","method":"T cell reporter assay platform, extensive binding studies (cis and trans configurations), T cell co-expression analysis, cytoplasmic domain signaling assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays and reporter systems, single lab; clearly negative interaction result combined with positive finding that TIM-3 cytoplasmic domain drives inhibitory signaling independently","pmids":["32222966"],"is_preprint":false},{"year":2024,"finding":"Among TIM-3 ligands tested on NK cells, galectin-9 most consistently suppresses NK cell-mediated cytotoxicity and proliferation through TIM-3 signaling, while also promoting IFN-γ release in a TIM-3-dependent manner. Galectin-9-mediated suppression of proliferation also occurred through CD44 signaling (independent of TIM-3).","method":"In vitro NK cell killing, proliferation, and cytokine production assays with four TIM-3 ligands (galectin-9, PtdSer, HMGB1, CEACAM1), TIM-3-blocking antibodies, HNSCC patient NK cell studies, flow cytometry","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple ligands compared in functional assays with receptor-blocking controls, patient samples included; single lab","pmids":["39773563"],"is_preprint":false},{"year":2020,"finding":"TIM-3 expression in Jurkat T cells is associated with decreased glucose uptake and consumption, reduced lactate release, and decreased Glut1 (but not Glut2/3/4) expression, indicating TIM-3 suppresses T cell glycolysis.","method":"TIM-3 overexpression and knockout in Jurkat T cells, glucose uptake/consumption assays, lactate release measurement, glucose transporter expression analysis","journal":"BMC immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single cell line model with overexpression and KO, correlation of TIM-3 with metabolic readouts without defined signaling mechanism; single lab","pmids":["32819283"],"is_preprint":false},{"year":2022,"finding":"Inhibition of melanoma cell-intrinsic TIM-3 promotes tumor growth via enhanced phosphorylation of MAPK signaling mediators (pro-proliferative). Melanoma-specific TIM-3 overexpression attenuated tumorigenesis in both immunocompetent and immunocompromised mice. Pharmacologic MAPK inhibition reversed TIM-3-antibody-mediated tumor growth promotion.","method":"Melanoma-specific TIM-3 knockdown and overexpression in vivo (immunocompetent and T-cell-deficient mice), MAPK phosphorylation assays, MEK inhibitor combination experiments","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined MAPK pathway mechanism, multiple mouse models, pharmacologic rescue; single lab","pmids":["35980306"],"is_preprint":false}],"current_model":"TIM-3 (HAVCR2) is a type I transmembrane immune checkpoint receptor with multiple ligands (galectin-9, phosphatidylserine, HMGB1) that exerts context-dependent co-inhibitory or co-stimulatory functions across immune cell types: on T cells it engages PS to promote NF-κB/IL-2 signaling acutely but drives exhaustion chronically; on dendritic cells it suppresses ROS/NLRP3 inflammasome activation and IL-1β/IL-18 production to restrain anti-tumor immunity; on NK cells it inhibits PI3K/Akt/mTORC1 signaling (via competition for the p85 subunit) to dampen cytotoxicity; it regulates microglial homeostasis by interacting with SMAD2/TGFBR2 to enhance TGFβ signaling; its surface stability is controlled by DHHC9-mediated palmitoylation at Cys296, which prevents HRD1-mediated ubiquitination and degradation; and its adaptor protein Bat3 binds its cytoplasmic tail to modulate DC steroidogenesis and T cell priming."},"narrative":{"mechanistic_narrative":"HAVCR2 (TIM-3) is a type I transmembrane immune receptor that exerts context-dependent co-stimulatory and co-inhibitory control across immune and non-immune cell types through multiple ligands and intracellular adaptors [PMID:16286920, PMID:34435619, PMID:31848194]. Several ligands engage its IgV domain: galectin-9 binding triggers calcium flux and selective death of TH1 cells [PMID:16286920] and suppresses NK cytotoxicity and proliferation [PMID:39773563]; phosphatidylserine engagement drives TCR-proximal NF-κB signaling and IL-2 secretion in T cells [PMID:34435619] but on NK cells promotes TIM-3 phosphorylation that lets it compete with PI3K p110 for the p85 regulatory subunit, suppressing Akt/mTORC1 signaling and cytotoxicity [PMID:31848194]; and HMGB1 binding inhibits NF-κB in CD4+ T cells during sepsis [PMID:34933101]. On dendritic cells TIM-3 restrains anti-tumor immunity by preventing ROS-driven NLRP3 inflammasome activation and IL-1β/IL-18 production [PMID:34108686], and mediates phosphatidylserine-dependent trogocytosis of CD8+ T cells [PMID:35316223]; its cytoplasmic-tail adaptor Bat3 limits DC steroidogenesis and the unfolded protein response to preserve effector T cell responses [PMID:35275752]. In microglia, TGFβ-induced TIM-3 interacts with SMAD2 and TGFBR2 through its C-terminal tail to enhance SMAD2 phosphorylation and maintain homeostasis, restraining a neurodegenerative phenotype [PMID:40205047]. Surface abundance is set post-translationally: DHHC9-mediated palmitoylation at Cys296 blocks HRD1-dependent ubiquitination and degradation, stabilizing the receptor and promoting exhaustion [PMID:39546589]. Germline missense mutations (p.Tyr82Cys, p.Ile97Met) that misfold the protein and abolish surface expression cause hemophagocytic lymphohistiocytosis and subcutaneous panniculitis-like T-cell lymphoma through persistent immune activation and TNF-α/IL-1β hypersecretion [PMID:30374066].","teleology":[{"year":2005,"claim":"Establishing the first functional ligand answered how TIM-3 transmits a regulatory signal, defining galectin-9 as a ligand that eliminates TH1 cells and suppresses autoimmunity.","evidence":"Calcium flux, cell aggregation/death assays in Tim-3+ T cells and in vivo galectin-9 administration in mouse autoimmunity","pmids":["16286920"],"confidence":"High","gaps":["Did not resolve the binding interface or downstream signaling biochemistry","Human-system relevance later contested"]},{"year":2013,"claim":"A negative report challenged the galectin-9 model by failing to detect specific binding to human or murine TIM-3, raising the question of which ligand drives human T cell function.","evidence":"Binding studies and T cell activation assays in human and murine systems plus HIV patient T cell assays","pmids":["23555261"],"confidence":"Medium","gaps":["Negative binding result does not exclude low-affinity or context-dependent interaction","Single-lab discrepancy with prior in vivo data"]},{"year":2015,"claim":"Identifying a co-stimulatory role in mast cells showed TIM-3 is not exclusively inhibitory, augmenting FcεRI-proximal Lyn-dependent signaling.","evidence":"Gain- and loss-of-function in mast cells with Lyn pathway, degranulation and cytokine readouts","pmids":["26598760"],"confidence":"High","gaps":["Direct ligand driving mast cell signaling not defined","Cytoplasmic motifs mediating Lyn engagement not mapped"]},{"year":2018,"claim":"Germline loss-of-function mutations established TIM-3 as a causal restraint on inflammation in humans, linking surface loss to hyperinflammatory disease.","evidence":"Sequencing, surface-expression analysis and cytokine quantification in HLH/SPTCL patients with cell models","pmids":["30374066"],"confidence":"High","gaps":["Cell type responsible for the inflammatory phenotype not pinpointed","Mechanism connecting misfolding to cytokine hypersecretion not fully defined"]},{"year":2019,"claim":"Defining the NK-cell mechanism showed how PS engagement converts TIM-3 into an inhibitor of metabolic-cytotoxic signaling by competing for PI3K p85.","evidence":"Phosphorylation and competitive p85-binding assays, Akt/mTORC1 analysis, NK functional assays and in vivo HCC model","pmids":["31848194"],"confidence":"High","gaps":["Phosphorylation residues mediating p85 competition not enumerated","Generality beyond NK cells unresolved"]},{"year":2021,"claim":"Reconciling co-stimulatory vs co-inhibitory roles, PS-binding-site mutagenesis showed PS engagement in T cells promotes NF-κB/IL-2 and alters CD28 phosphorylation, defining a context-dependent acute signal.","evidence":"PS-binding-site mutagenesis, NF-κB reporter, IL-2 ELISA, CD28 phosphorylation and antibody blockade in Jurkat cells","pmids":["34435619"],"confidence":"High","gaps":["How the same PS ligand yields opposite outcomes across cell types not mechanistically unified","Endogenous T cell validation beyond Jurkat needed"]},{"year":2021,"claim":"Cell-type-specific knockouts revealed the dominant anti-tumor checkpoint function resides in dendritic cells, where TIM-3 suppresses the NLRP3 inflammasome.","evidence":"Conditional DC/CD4/CD8 KO with genetic epistasis, scRNA-seq, ROS and inflammasome assays, IL-1β/IL-18 blockade and tumor models","pmids":["34108686"],"confidence":"High","gaps":["Molecular link from TIM-3 to ROS/NLRP3 suppression not biochemically defined","Ligand driving DC-intrinsic signal not identified"]},{"year":2021,"claim":"TIM-3 was shown to act intracellularly in macrophages, targeting the viral sensor NF90 for TRIM47-mediated K48 ubiquitination to suppress antiviral innate immunity.","evidence":"Co-IP, K48 ubiquitination and domain-mapping assays, Tim-3 inactivation, stress-granule and eIF2α/PKR readouts and in vivo VSV challenge","pmids":["34110282"],"confidence":"High","gaps":["How a surface receptor accesses cytoplasmic NF90 not resolved","Relationship to canonical ligand-driven signaling unclear"]},{"year":2021,"claim":"HMGB1 was identified as a TIM-3 ligand inhibiting NF-κB in CD4+ T cells, contributing to sepsis-induced immunosuppression.","evidence":"Colocalization of HMGB1 and TIM-3, NF-κB analysis, conditional Tim-3 deletion and sepsis mortality model","pmids":["34933101"],"confidence":"Medium","gaps":["Interaction based on colocalization rather than direct biochemical binding","Binding interface unmapped"]},{"year":2022,"claim":"The Bat3 adaptor was defined as an endogenous regulator of the TIM-3 tail, controlling DC steroidogenesis and the UPR to shape T cell quality.","evidence":"Bat3 conditional DC deletion, EAE and MC38-OVA models, steroidogenesis and acetyl-CoA assays, T cell phenotyping","pmids":["35275752"],"confidence":"High","gaps":["Direct structural basis of Bat3 tail binding not detailed","Whether ligand engagement modulates Bat3 release unknown"]},{"year":2022,"claim":"A trogocytosis mechanism explained how DC-intrinsic TIM-3 produces fratricide of tumor-reactive CD8+ T cells via PS-dependent membrane transfer.","evidence":"Human melanoma TIL analysis, PS-blocking, DC-specific conditional KO and two melanoma models with trogocytosis/fratricide assays","pmids":["35316223"],"confidence":"High","gaps":["Molecular machinery executing membrane transfer downstream of TIM-3 not defined"]},{"year":2022,"claim":"Tumor-cell-intrinsic TIM-3 roles were defined: in glioblastoma it drives NF-κB/IL-6 to polarize macrophages, and in melanoma it restrains pro-proliferative MAPK signaling.","evidence":"Gain/loss-of-function in glioma and melanoma cells, NF-κB/IL-6 and MAPK pathway analyses, macrophage co-culture and in vivo pharmacologic rescue","pmids":["36325060","35980306"],"confidence":"Medium","gaps":["Cancer-cell-intrinsic ligands and proximal signaling steps undefined","Single-lab findings per tumor type"]},{"year":2024,"claim":"Post-translational control of receptor abundance was established: DHHC9-mediated Cys296 palmitoylation blocks HRD1 binding and degradation, a node exploitable to reduce exhaustion.","evidence":"Palmitoylation and Cys296 mutagenesis, Co-IP with HRD1, ubiquitination assays, DHHC9 knockdown, CAR-T exhaustion and peptidic inhibitor experiments","pmids":["39546589"],"confidence":"High","gaps":["Whether palmitoylation status is signal-regulated in vivo unclear","Stoichiometry with HRD1 vs other ligases not resolved"]},{"year":2024,"claim":"Comparative ligand testing on NK cells re-affirmed galectin-9 as the most consistent suppressive ligand while revealing TIM-3-independent CD44 signaling.","evidence":"NK killing, proliferation and cytokine assays with four ligands, TIM-3-blocking antibodies and HNSCC patient NK cells","pmids":["39773563"],"confidence":"Medium","gaps":["Relative ligand affinities and binding sites not biochemically ranked","Single-lab functional comparison"]},{"year":2025,"claim":"A non-immune homeostatic role was defined: TGFβ-induced microglial TIM-3 binds SMAD2/TGFBR2 to amplify SMAD2 phosphorylation, restraining a neurodegenerative microglial phenotype.","evidence":"Co-IP (TIM-3 with SMAD2 and TGFBR2), SMAD2 phosphorylation assays, microglia-specific Havcr2 KO, 5xFAD model and sc/snRNA-seq","pmids":["40205047"],"confidence":"High","gaps":["Structural basis of TIM-3 tail engagement with SMAD2/TGFBR2 not resolved","Whether ligand binding gates this interaction unknown"]},{"year":null,"claim":"A unifying biochemical model for how a single cytoplasmic tail toggles between activating (NF-κB/IL-2), inhibitory (PI3K competition), degradative (NF90/TRIM47), and adaptor/scaffold (Bat3, SMAD2/TGFBR2) functions across cell types remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structure of the signaling-competent tail with its partners","Ligand-specific signaling outputs not mechanistically separated","Conflicting galectin-9 binding data across human/murine systems unreconciled"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[4,6,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,9,11]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[9,11]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,10]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,4,5,8]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,6,11]}],"complexes":[],"partners":["LGALS9","PIK3R1","BAG6","ZBTB32","SMAD2","TGFBR2","SYVN1","ZDHHC9"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TDQ0","full_name":"Hepatitis A virus cellular receptor 2","aliases":["T-cell immunoglobulin and mucin domain-containing protein 3","TIMD-3","T-cell immunoglobulin mucin receptor 3","TIM-3","T-cell membrane protein 3"],"length_aa":301,"mass_kda":33.4,"function":"Cell surface receptor implicated in modulating innate and adaptive immune responses. Generally accepted to have an inhibiting function. Reports on stimulating functions suggest that the activity may be influenced by the cellular context and/or the respective ligand (PubMed:24825777). Regulates macrophage activation (PubMed:11823861). Inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance (PubMed:14556005). In CD8+ cells attenuates TCR-induced signaling, specifically by blocking NF-kappaB and NFAT promoter activities resulting in the loss of IL-2 secretion. The function may implicate its association with LCK proposed to impair phosphorylation of TCR subunits, and/or LGALS9-dependent recruitment of PTPRC to the immunological synapse (PubMed:24337741, PubMed:26492563). In contrast, shown to activate TCR-induced signaling in T-cells probably implicating ZAP70, LCP2, LCK and FYN (By similarity). Expressed on Treg cells can inhibit Th17 cell responses (PubMed:24838857). Receptor for LGALS9 (PubMed:16286920, PubMed:24337741). Binding to LGALS9 is believed to result in suppression of T-cell responses; the resulting apoptosis of antigen-specific cells may implicate HAVCR2 phosphorylation and disruption of its association with BAG6. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens. Expressed on Th1 cells interacts with LGALS9 expressed on Mycobacterium tuberculosis-infected macrophages to stimulate antibactericidal activity including IL-1 beta secretion and to restrict intracellular bacterial growth (By similarity). However, the function as receptor for LGALS9 has been challenged (PubMed:23555261). Also reported to enhance CD8+ T-cell responses to an acute infection such as by Listeria monocytogenes (By similarity). Receptor for phosphatidylserine (PtSer); PtSer-binding is calcium-dependent. May recognize PtSer on apoptotic cells leading to their phagocytosis. Mediates the engulfment of apoptotic cells by dendritic cells. Expressed on T-cells, promotes conjugation but not engulfment of apoptotic cells. Expressed on dendritic cells (DCs) positively regulates innate immune response and in synergy with Toll-like receptors promotes secretion of TNF. In tumor-imfiltrating DCs suppresses nucleic acid-mediated innate immune repsonse by interaction with HMGB1 and interfering with nucleic acid-sensing and trafficking of nucleid acids to endosomes (By similarity). Expressed on natural killer (NK) cells acts as a coreceptor to enhance IFN-gamma production in response to LGALS9 (PubMed:22323453). In contrast, shown to suppress NK cell-mediated cytotoxicity (PubMed:22383801). Negatively regulates NK cell function in LPS-induced endotoxic shock (By similarity)","subcellular_location":"Cell membrane; Cell junction; Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q8TDQ0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HAVCR2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HAVCR2","total_profiled":1310},"omim":[{"mim_id":"618398","title":"T-CELL LYMPHOMA, SUBCUTANEOUS PANNICULITIS-LIKE; SPTCL","url":"https://www.omim.org/entry/618398"},{"mim_id":"611162","title":"MALARIA, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/611162"},{"mim_id":"608863","title":"PODOPLANIN; PDPN","url":"https://www.omim.org/entry/608863"},{"mim_id":"606863","title":"THYMOCYTE SELECTION-ASSOCIATED HIGH MOBILITY GROUP BOX; TOX","url":"https://www.omim.org/entry/606863"},{"mim_id":"606652","title":"HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HAVCR2","url":"https://www.omim.org/entry/606652"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/HAVCR2"},"hgnc":{"alias_symbol":["Tim-3","TIM3","FLJ14428","TIMD3","CD366"],"prev_symbol":[]},"alphafold":{"accession":"Q8TDQ0","domains":[{"cath_id":"2.60.40.10","chopping":"22-131","consensus_level":"medium","plddt":91.6359,"start":22,"end":131},{"cath_id":"1.20.5","chopping":"189-239","consensus_level":"medium","plddt":77.4049,"start":189,"end":239}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDQ0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDQ0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TDQ0-F1-predicted_aligned_error_v6.png","plddt_mean":71.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HAVCR2","jax_strain_url":"https://www.jax.org/strain/search?query=HAVCR2"},"sequence":{"accession":"Q8TDQ0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TDQ0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TDQ0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TDQ0"}},"corpus_meta":[{"pmid":"27192565","id":"PMC_27192565","title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27192565","citation_count":1722,"is_preprint":false},{"pmid":"16286920","id":"PMC_16286920","title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.","date":"2005","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16286920","citation_count":1669,"is_preprint":false},{"pmid":"28258697","id":"PMC_28258697","title":"Tim-3 and its role in regulating anti-tumor immunity.","date":"2017","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28258697","citation_count":698,"is_preprint":false},{"pmid":"33547304","id":"PMC_33547304","title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33547304","citation_count":520,"is_preprint":false},{"pmid":"32601081","id":"PMC_32601081","title":"Tim-3 finds its place in the cancer immunotherapy landscape.","date":"2020","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32601081","citation_count":337,"is_preprint":false},{"pmid":"34108686","id":"PMC_34108686","title":"TIM-3 restrains anti-tumour immunity by regulating inflammasome activation.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34108686","citation_count":324,"is_preprint":false},{"pmid":"37670328","id":"PMC_37670328","title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.","date":"2023","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37670328","citation_count":302,"is_preprint":false},{"pmid":"21697013","id":"PMC_21697013","title":"Emerging Tim-3 functions in antimicrobial and tumor immunity.","date":"2011","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21697013","citation_count":202,"is_preprint":false},{"pmid":"38354701","id":"PMC_38354701","title":"LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.","date":"2024","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/38354701","citation_count":201,"is_preprint":false},{"pmid":"28300768","id":"PMC_28300768","title":"TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28300768","citation_count":190,"is_preprint":false},{"pmid":"30410357","id":"PMC_30410357","title":"TIM-3, a promising target for cancer immunotherapy.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30410357","citation_count":187,"is_preprint":false},{"pmid":"30374066","id":"PMC_30374066","title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.","date":"2018","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30374066","citation_count":177,"is_preprint":false},{"pmid":"34224993","id":"PMC_34224993","title":"TIM-3: An update on immunotherapy.","date":"2021","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34224993","citation_count":173,"is_preprint":false},{"pmid":"22226204","id":"PMC_22226204","title":"Tim-3, a negative regulator of anti-tumor immunity.","date":"2012","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22226204","citation_count":169,"is_preprint":false},{"pmid":"24339828","id":"PMC_24339828","title":"Tim-3: an activation marker and activation limiter of innate immune cells.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24339828","citation_count":167,"is_preprint":false},{"pmid":"25086175","id":"PMC_25086175","title":"Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25086175","citation_count":141,"is_preprint":false},{"pmid":"20700701","id":"PMC_20700701","title":"TIM-3 and its regulatory role in immune responses.","date":"2011","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20700701","citation_count":132,"is_preprint":false},{"pmid":"31604535","id":"PMC_31604535","title":"Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance.","date":"2019","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31604535","citation_count":130,"is_preprint":false},{"pmid":"31848194","id":"PMC_31848194","title":"Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31848194","citation_count":128,"is_preprint":false},{"pmid":"28900677","id":"PMC_28900677","title":"Tim-3, Lag-3, and TIGIT.","date":"2017","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28900677","citation_count":126,"is_preprint":false},{"pmid":"23335978","id":"PMC_23335978","title":"Tim-3 expression in cervical cancer promotes tumor metastasis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23335978","citation_count":124,"is_preprint":false},{"pmid":"30309387","id":"PMC_30309387","title":"Tim-3 expression and its role in hepatocellular carcinoma.","date":"2018","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30309387","citation_count":117,"is_preprint":false},{"pmid":"28919992","id":"PMC_28919992","title":"Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.","date":"2017","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/28919992","citation_count":112,"is_preprint":false},{"pmid":"37567938","id":"PMC_37567938","title":"TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.","date":"2023","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/37567938","citation_count":105,"is_preprint":false},{"pmid":"27379093","id":"PMC_27379093","title":"TIM-3 Regulates Distinct Functions in Macrophages.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27379093","citation_count":104,"is_preprint":false},{"pmid":"26598760","id":"PMC_26598760","title":"Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26598760","citation_count":103,"is_preprint":false},{"pmid":"37802053","id":"PMC_37802053","title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.","date":"2023","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/37802053","citation_count":96,"is_preprint":false},{"pmid":"17011764","id":"PMC_17011764","title":"TIM-3 in autoimmunity.","date":"2006","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17011764","citation_count":90,"is_preprint":false},{"pmid":"29735977","id":"PMC_29735977","title":"Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice.","date":"2018","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29735977","citation_count":87,"is_preprint":false},{"pmid":"34933101","id":"PMC_34933101","title":"Tim-3 regulates sepsis-induced immunosuppression by inhibiting the NF-κB signaling pathway in CD4 T cells.","date":"2021","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34933101","citation_count":78,"is_preprint":false},{"pmid":"33334180","id":"PMC_33334180","title":"TIM-3 pathway dysregulation and targeting in cancer.","date":"2021","source":"Expert review of anticancer therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33334180","citation_count":77,"is_preprint":false},{"pmid":"29560265","id":"PMC_29560265","title":"Immune regulation by Tim-3.","date":"2018","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/29560265","citation_count":76,"is_preprint":false},{"pmid":"34631560","id":"PMC_34631560","title":"Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34631560","citation_count":75,"is_preprint":false},{"pmid":"23555261","id":"PMC_23555261","title":"TIM-3 does not act as a receptor for galectin-9.","date":"2013","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/23555261","citation_count":72,"is_preprint":false},{"pmid":"24825777","id":"PMC_24825777","title":"Regulation of T cell responses by the receptor molecule Tim-3.","date":"2014","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/24825777","citation_count":68,"is_preprint":false},{"pmid":"26008981","id":"PMC_26008981","title":"Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26008981","citation_count":68,"is_preprint":false},{"pmid":"39546589","id":"PMC_39546589","title":"Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39546589","citation_count":66,"is_preprint":false},{"pmid":"31726050","id":"PMC_31726050","title":"Tim-3 suppresses the killing effect of Vγ9Vδ2 T cells on colon cancer cells by reducing perforin and granzyme B expression.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/31726050","citation_count":62,"is_preprint":false},{"pmid":"18706830","id":"PMC_18706830","title":"TIM-1 and TIM-3 proteins in immune regulation.","date":"2008","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18706830","citation_count":62,"is_preprint":false},{"pmid":"35218498","id":"PMC_35218498","title":"New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.","date":"2022","source":"Current oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/35218498","citation_count":61,"is_preprint":false},{"pmid":"31747929","id":"PMC_31747929","title":"Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31747929","citation_count":59,"is_preprint":false},{"pmid":"35316223","id":"PMC_35316223","title":"Tim-3 mediates T cell trogocytosis to limit antitumor immunity.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/35316223","citation_count":58,"is_preprint":false},{"pmid":"38457514","id":"PMC_38457514","title":"Beyond T cell exhaustion: TIM-3 regulation of myeloid cells.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38457514","citation_count":55,"is_preprint":false},{"pmid":"34660319","id":"PMC_34660319","title":"TIM-3 in Leukemia; Immune Response and Beyond.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34660319","citation_count":53,"is_preprint":false},{"pmid":"26253654","id":"PMC_26253654","title":"Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.","date":"2015","source":"World journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/26253654","citation_count":53,"is_preprint":false},{"pmid":"30377566","id":"PMC_30377566","title":"TIM-3 expression in breast cancer.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30377566","citation_count":51,"is_preprint":false},{"pmid":"26211834","id":"PMC_26211834","title":"Tim-3 and Tim-4 as the potential targets for antitumor therapy.","date":"2015","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26211834","citation_count":49,"is_preprint":false},{"pmid":"28035413","id":"PMC_28035413","title":"Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28035413","citation_count":48,"is_preprint":false},{"pmid":"30876792","id":"PMC_30876792","title":"NK cell expression of Tim-3: First impressions matter.","date":"2019","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30876792","citation_count":47,"is_preprint":false},{"pmid":"40205047","id":"PMC_40205047","title":"Immune checkpoint TIM-3 regulates microglia and Alzheimer's disease.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40205047","citation_count":46,"is_preprint":false},{"pmid":"35275752","id":"PMC_35275752","title":"Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35275752","citation_count":46,"is_preprint":false},{"pmid":"33425759","id":"PMC_33425759","title":"The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33425759","citation_count":45,"is_preprint":false},{"pmid":"36325060","id":"PMC_36325060","title":"Cancer cell intrinsic TIM-3 induces glioblastoma progression.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/36325060","citation_count":43,"is_preprint":false},{"pmid":"34435619","id":"PMC_34435619","title":"Phosphatidylserine binding directly regulates TIM-3 function.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/34435619","citation_count":43,"is_preprint":false},{"pmid":"27792886","id":"PMC_27792886","title":"Tim-3: Expression on immune cells and roles at the maternal-fetal interface.","date":"2016","source":"Journal of reproductive immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27792886","citation_count":42,"is_preprint":false},{"pmid":"38640253","id":"PMC_38640253","title":"TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38640253","citation_count":41,"is_preprint":false},{"pmid":"26551150","id":"PMC_26551150","title":"Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.","date":"2015","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26551150","citation_count":40,"is_preprint":false},{"pmid":"36359346","id":"PMC_36359346","title":"The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36359346","citation_count":39,"is_preprint":false},{"pmid":"33868234","id":"PMC_33868234","title":"One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33868234","citation_count":39,"is_preprint":false},{"pmid":"26900291","id":"PMC_26900291","title":"Role of Tim-3 in hepatitis B virus infection: An overview.","date":"2016","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26900291","citation_count":37,"is_preprint":false},{"pmid":"40332725","id":"PMC_40332725","title":"TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives.","date":"2025","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/40332725","citation_count":35,"is_preprint":false},{"pmid":"38330550","id":"PMC_38330550","title":"Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38330550","citation_count":34,"is_preprint":false},{"pmid":"32094297","id":"PMC_32094297","title":"Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32094297","citation_count":33,"is_preprint":false},{"pmid":"35280800","id":"PMC_35280800","title":"Tim-3 Blockade Elicits Potent Anti-Multiple Myeloma Immunity of Natural Killer Cells.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35280800","citation_count":33,"is_preprint":false},{"pmid":"34159709","id":"PMC_34159709","title":"TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34159709","citation_count":32,"is_preprint":false},{"pmid":"19768575","id":"PMC_19768575","title":"TIM-3 as a new therapeutic target in systemic lupus erythematosus.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19768575","citation_count":31,"is_preprint":false},{"pmid":"35226805","id":"PMC_35226805","title":"Photophosphatidylserine Guides Natural Killer Cell Photoimmunotherapy via Tim-3.","date":"2022","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/35226805","citation_count":29,"is_preprint":false},{"pmid":"32819283","id":"PMC_32819283","title":"Association of TIM-3 expression with glucose metabolism in Jurkat T cells.","date":"2020","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32819283","citation_count":28,"is_preprint":false},{"pmid":"17665973","id":"PMC_17665973","title":"TIM-3 as a therapeutic target in human inflammatory diseases.","date":"2007","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/17665973","citation_count":28,"is_preprint":false},{"pmid":"32222966","id":"PMC_32222966","title":"TIM-3 and CEACAM1 do not interact in cis and in trans.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32222966","citation_count":27,"is_preprint":false},{"pmid":"35464400","id":"PMC_35464400","title":"Tim-3 Expression Causes NK Cell Dysfunction in Type 2 Diabetes Patients.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35464400","citation_count":27,"is_preprint":false},{"pmid":"31486085","id":"PMC_31486085","title":"TIM-3: An emerging target in the liver diseases.","date":"2020","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31486085","citation_count":26,"is_preprint":false},{"pmid":"36739094","id":"PMC_36739094","title":"Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases.","date":"2023","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36739094","citation_count":26,"is_preprint":false},{"pmid":"35095844","id":"PMC_35095844","title":"Tim-3 Relieves Experimental Autoimmune Encephalomyelitis by Suppressing MHC-II.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35095844","citation_count":25,"is_preprint":false},{"pmid":"39396768","id":"PMC_39396768","title":"The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39396768","citation_count":24,"is_preprint":false},{"pmid":"34110282","id":"PMC_34110282","title":"Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34110282","citation_count":23,"is_preprint":false},{"pmid":"33889713","id":"PMC_33889713","title":"ImmunoPET Imaging of TIM-3 in Murine Melanoma Models.","date":"2020","source":"Advanced therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33889713","citation_count":23,"is_preprint":false},{"pmid":"40345189","id":"PMC_40345189","title":"Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.","date":"2025","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/40345189","citation_count":22,"is_preprint":false},{"pmid":"37894310","id":"PMC_37894310","title":"TIM-3 Expression and M2 Polarization of Macrophages in the TGFβ-Activated Tumor Microenvironment in Colorectal Cancer.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37894310","citation_count":22,"is_preprint":false},{"pmid":"29551917","id":"PMC_29551917","title":"On the significance of Tim-3 expression in pancreatic cancer.","date":"2017","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29551917","citation_count":21,"is_preprint":false},{"pmid":"26050547","id":"PMC_26050547","title":"Tim-3 pathway affects NK cell impairment in patients with active tuberculosis.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26050547","citation_count":21,"is_preprint":false},{"pmid":"28132803","id":"PMC_28132803","title":"Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28132803","citation_count":21,"is_preprint":false},{"pmid":"37290326","id":"PMC_37290326","title":"T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37290326","citation_count":20,"is_preprint":false},{"pmid":"35250975","id":"PMC_35250975","title":"Increased Expression of Tim-3 Is Associated With Depletion of NKT Cells In SARS-CoV-2 Infection.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35250975","citation_count":20,"is_preprint":false},{"pmid":"29553498","id":"PMC_29553498","title":"Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells.","date":"2018","source":"Journal of visualized experiments : JoVE","url":"https://pubmed.ncbi.nlm.nih.gov/29553498","citation_count":19,"is_preprint":false},{"pmid":"35980306","id":"PMC_35980306","title":"Inhibition of Melanoma Cell-Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35980306","citation_count":19,"is_preprint":false},{"pmid":"17331850","id":"PMC_17331850","title":"Tim-3 expression in human kidney allografts.","date":"2006","source":"Transplant immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17331850","citation_count":19,"is_preprint":false},{"pmid":"32320745","id":"PMC_32320745","title":"Differential expression of TIM-3 in circulation and tumor microenvironment of colorectal cancer patients.","date":"2020","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/32320745","citation_count":19,"is_preprint":false},{"pmid":"31938210","id":"PMC_31938210","title":"Expression of Tim-3 in breast cancer tissue promotes tumor progression.","date":"2018","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31938210","citation_count":19,"is_preprint":false},{"pmid":"38916965","id":"PMC_38916965","title":"Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38916965","citation_count":18,"is_preprint":false},{"pmid":"28357631","id":"PMC_28357631","title":"Role of TIM-3 in ovarian cancer.","date":"2017","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/28357631","citation_count":18,"is_preprint":false},{"pmid":"29254227","id":"PMC_29254227","title":"High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29254227","citation_count":18,"is_preprint":false},{"pmid":"32665122","id":"PMC_32665122","title":"TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer.","date":"2020","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32665122","citation_count":17,"is_preprint":false},{"pmid":"29602251","id":"PMC_29602251","title":"Tim-3 blockade promotes iNKT cell function to inhibit HBV replication.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29602251","citation_count":17,"is_preprint":false},{"pmid":"33041828","id":"PMC_33041828","title":"Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33041828","citation_count":17,"is_preprint":false},{"pmid":"33103506","id":"PMC_33103506","title":"Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential.","date":"2020","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/33103506","citation_count":17,"is_preprint":false},{"pmid":"33728805","id":"PMC_33728805","title":"Tim-3 suppresses autoimmune hepatitis via the p38/MKP-1 pathway in Th17 cells.","date":"2021","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/33728805","citation_count":17,"is_preprint":false},{"pmid":"36980583","id":"PMC_36980583","title":"T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36980583","citation_count":16,"is_preprint":false},{"pmid":"27809352","id":"PMC_27809352","title":"T-bet-mediated Tim-3 expression dampens monocyte function during chronic hepatitis C virus infection.","date":"2016","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27809352","citation_count":16,"is_preprint":false},{"pmid":"39773563","id":"PMC_39773563","title":"Differential impact of TIM-3 ligands on NK cell function.","date":"2025","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39773563","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44811,"output_tokens":6484,"usd":0.115847,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15489,"output_tokens":4972,"usd":0.100873,"stage2_stop_reason":"end_turn"},"total_usd":0.21672,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Galectin-9 was identified as a functional ligand for TIM-3. Galectin-9 binding to TIM-3 induced intracellular calcium flux, cell aggregation, and selective death of TH1 cells in vitro; in vivo administration caused loss of IFN-γ-producing cells and suppression of TH1 autoimmunity in a TIM-3-dependent manner.\",\n      \"method\": \"In vitro calcium flux assay, cell aggregation/death assays with Tim-3-expressing T cells, in vivo galectin-9 administration in mouse autoimmunity model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal in vitro assays plus in vivo validation, replicated across subsequent studies; ligand-receptor interaction established functionally\",\n      \"pmids\": [\"16286920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NEGATIVE FINDING: Extensive binding studies did not yield evidence for specific interaction between galectin-9 and human or murine TIM-3, and galectin-9 did not affect activation of human T cells. Anti-TIM-3 antibodies failed to increase anti-HIV T cell responses in vitro.\",\n      \"method\": \"T cell activation assays, extensive binding studies (human and murine TIM-3 vs. galectin-9), HIV patient T cell functional assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal binding and functional assays in a single lab; contradicts PMID 16286920 but uses human system specifically\",\n      \"pmids\": [\"23555261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIM-3 enhances FcεRI-proximal signaling in mast cells by acting at a receptor-proximal point to augment Lyn kinase-dependent pathways, thereby modulating both immediate-phase degranulation and late-phase cytokine production downstream of FcεRI ligation.\",\n      \"method\": \"Gain- and loss-of-function approaches in mast cells, signaling pathway analysis (Lyn kinase), degranulation and cytokine production assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with defined signaling readout, multiple orthogonal assays in a single rigorous study\",\n      \"pmids\": [\"26598760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Germline missense mutations in HAVCR2 (p.Tyr82Cys and p.Ile97Met) cause protein misfolding and abolish TIM-3 plasma membrane expression, leading to persistent immune activation and increased production of TNF-α and IL-1β, promoting hemophagocytic lymphohistiocytosis (HLH) and subcutaneous panniculitis-like T cell lymphoma (SPTCL).\",\n      \"method\": \"Genetic sequencing, protein expression analysis (Western blot/surface expression), cytokine quantification in patient samples and cell models\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mutations with defined molecular (protein misfolding, loss of surface expression) and cellular (cytokine hypersecretion) phenotypes in human patient cohort with functional validation\",\n      \"pmids\": [\"30374066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Phosphatidylserine (PtdSer) engagement promotes phosphorylation of TIM-3 on NK cells, which then competes with PI3K p110 subunit to bind the p85 regulatory subunit, thereby inhibiting downstream Akt/mTORC1 signaling and suppressing NK cell cytokine secretion and cytotoxic activity in hepatocellular carcinoma.\",\n      \"method\": \"Phosphorylation assays, competitive binding of TIM-3 vs. PI3K p110 for p85, Akt/mTORC1 pathway analysis, NK cell functional assays, in vivo HCC tumor model with TIM-3 blockade\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — defined biochemical mechanism (TIM-3 phosphorylation, competitive p85 binding) with downstream signaling validation and in vivo confirmation in a single rigorous study\",\n      \"pmids\": [\"31848194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TIM-3 on dendritic cells (DCs) restrains anti-tumor immunity by preventing NLRP3 inflammasome activation; loss of TIM-3 in DCs leads to increased reactive oxygen species accumulation, NLRP3 inflammasome activation, and IL-1β/IL-18-dependent promotion of CD8+ effector and stem-like T cells. TIM-3 deletion in DCs—but not in CD4+ or CD8+ T cells—was responsible for the anti-tumor effect.\",\n      \"method\": \"Conditional knockout of TIM-3 in DCs, CD4+ T cells, and CD8+ T cells (cell-type-specific genetic epistasis); single-cell RNA sequencing; ROS measurement; inflammasome activity assays; IL-1β/IL-18 blockade experiments; tumor growth assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — conditional cell-type-specific KO with genetic epistasis, multiple orthogonal mechanistic assays, scRNA-seq, and pharmacologic rescue in a rigorous single study\",\n      \"pmids\": [\"34108686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TIM-3 binding to phosphatidylserine (PS) promotes NF-κB signaling and IL-2 secretion downstream of TCR stimulation in Jurkat T cells; this co-stimulatory activity is blocked by mutating the PS-binding site or by occluding it with antibody. TIM-3 signaling also alters CD28 phosphorylation.\",\n      \"method\": \"PS-binding site mutagenesis, NF-κB reporter assays, IL-2 ELISA, CD28 phosphorylation analysis, antibody blockade of PS-binding site in Jurkat cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with signaling assays and antibody blockade, multiple orthogonal methods in one study establishing PS as functional ligand for TIM-3 signaling\",\n      \"pmids\": [\"34435619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TIM-3 promotes ubiquitination and proteasomal degradation of NF90 (a virus sensor) in macrophages during VSV infection by recruiting E3 ubiquitin ligase TRIM47 to the zinc finger domain of NF90, initiating K48-linked ubiquitination at Lys297, thereby suppressing stress granule formation and antiviral innate immunity.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays (K48-linkage), domain mapping, Tim-3 conditional inactivation, downstream stress granule marker analysis (G3BP1, TIA-1), eIF2α/PKR phosphorylation assays, in vivo VSV challenge\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — biochemical mechanism defined at residue level (Lys297) with Co-IP, ubiquitination assays, multiple downstream readouts, and in vivo validation in a single rigorous study\",\n      \"pmids\": [\"34110282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TIM-3 on dendritic cells (APCs) mediates trogocytosis—transfer of membrane fragments from APCs to T cells. TIM-3 blockade on Tim-3+ APCs disrupted phosphatidylserine-dependent trogocytosis of activated CD8+ T cells and PD-1+Tim-3+ TILs. Trogocytosed CD8+ T cells presented tumor peptide-MHC complexes and became targets of fratricide killing, which was reversed by TIM-3 blockade. Conditional deletion of TIM-3 in DCs but not CD8+ T cells impeded trogocytosis in vivo.\",\n      \"method\": \"Human melanoma TIL analysis, PS-blocking experiments, DC-specific TIM-3 conditional deletion in vivo, two melanoma mouse models, functional assays for trogocytosis and fratricide T cell killing\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — DC-specific conditional KO with defined cellular mechanism, PS-dependent trogocytosis validated in multiple models and patient samples, orthogonal methods\",\n      \"pmids\": [\"35316223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Bat3, an adaptor protein that binds the cytoplasmic tail of TIM-3, acts as an endogenous regulator of DC function. Loss of Bat3 in DCs leads to hyperactive unfolded protein response and redirects acetyl-CoA toward increased cell-intrinsic steroidogenesis, which suppresses T cell responses in a paracrine manner; this skews the immune response toward regulatory T cells and exhausted CD8+ TILs.\",\n      \"method\": \"Bat3 conditional deletion in DCs, autoimmunity (EAE) and cancer (MC38-OVA) mouse models, steroidogenesis assays, acetyl-CoA metabolic analysis, T cell compartment phenotyping\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined metabolic mechanism, multiple in vivo disease models, orthogonal metabolic and immunologic assays in a single rigorous study\",\n      \"pmids\": [\"35275752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TIM-3 is palmitoylated by the palmitoyltransferase DHHC9 at cysteine 296 (Cys296). Palmitoylation stabilizes TIM-3 by preventing its binding to E3 ubiquitin ligase HRD1, thereby suppressing TIM-3 polyubiquitination and degradation. DHHC9 knockdown attenuated CAR-T cell exhaustion, and a peptidic inhibitor of TIM-3 palmitoylation accelerated TIM-3 degradation and enhanced antitumor immunity.\",\n      \"method\": \"Palmitoylation assays, site-directed mutagenesis (Cys296), Co-IP with HRD1, ubiquitination assays, DHHC9 knockdown, CAR-T cell exhaustion assays, peptidic inhibitor experiments\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — palmitoylation at specific residue identified with mutagenesis, biochemical interaction with HRD1 shown by Co-IP, ubiquitination rescue experiments, and functional validation in CAR-T cells\",\n      \"pmids\": [\"39546589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TGFβ signaling induces TIM-3 expression in microglia. TIM-3 in turn interacts with SMAD2 and TGFBR2 through its C-terminal tail, enhancing TGFβ signaling by promoting TGFBR-mediated SMAD2 phosphorylation; this maintains microglial homeostasis. Microglial-specific deletion of Havcr2 increases phagocytic activity and shifts microglia toward a neurodegenerative (MGnD/DAM) phenotype, ameliorating amyloid-β pathology and cognitive impairment in 5×FAD mice.\",\n      \"method\": \"Co-immunoprecipitation (TIM-3 with SMAD2 and TGFBR2), SMAD2 phosphorylation assays, microglia-specific conditional Havcr2 knockout (Cre-lox), 5×FAD Alzheimer's model behavioral and pathology analyses, single-nucleus and single-cell RNA sequencing\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP defining interaction partners, phosphorylation assays, cell-type-specific conditional KO, in vivo disease model rescue, and transcriptomic validation constitute multiple orthogonal rigorous methods\",\n      \"pmids\": [\"40205047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In CD4+ T cells during sepsis, HMGB1 binds to TIM-3 and this interaction inhibits the NF-κB signaling pathway in TIM-3+ CD4+ T cells, contributing to sepsis-induced immunosuppression. Conditional or systemic deletion of Tim-3 reduced sepsis mortality.\",\n      \"method\": \"Colocalization analysis of HMGB1 and TIM-3 on CD4+ T cells, NF-κB signaling pathway analysis, conditional Tim-3 deletion in CD4+ T cells, in vivo sepsis mouse model mortality assay\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — colocalization plus conditional KO with pathway analysis, but binding mechanism based on colocalization rather than direct biochemical interaction assay\",\n      \"pmids\": [\"34933101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tim-3 signaling in Vγ9Vδ2 T cells reduces perforin and granzyme B expression through an ERK1/2-dependent pathway, thereby suppressing cytotoxic killing of colon cancer cells.\",\n      \"method\": \"Tim-3 signaling activation experiments, perforin/granzyme B expression analysis, ERK1/2 pathway inhibition, cytotoxicity assays against colon cancer cells\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — defined signaling pathway (ERK1/2) linking TIM-3 to effector molecule expression with functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"31726050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In glioblastoma cells, TIM-3 regulates IL-6 expression through NF-κB activation; cell-intrinsic TIM-3/IL-6 signaling induces macrophage migration and M2/anti-inflammatory polarization. Blocking IL-6 receptor with tocilizumab suppressed these effects and repressed GBM tumorigenicity in vivo.\",\n      \"method\": \"TIM-3 overexpression/knockdown in glioma cells, NF-κB pathway analysis, IL-6 quantification, macrophage co-culture migration and polarization assays, in vivo GBM tumor model with tocilizumab treatment\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — gain- and loss-of-function with defined NF-κB/IL-6 mechanism, macrophage functional readout, and in vivo pharmacologic rescue; single lab\",\n      \"pmids\": [\"36325060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tim-3 expressed in macrophages suppresses neutrophil necroptosis during colitis by inhibiting the TLR4/NF-κB pathway; macrophage-specific Tim-3 knockout increased ROS-driven neutrophil necroptosis and colitis severity. RIP1/RIP3 or ROS inhibition reversed the inflammation in Tim-3 KO mice.\",\n      \"method\": \"Macrophage-specific Tim-3 conditional knockout mice, DSS-induced colitis model, TLR4/NF-κB pathway analysis, RIP1/RIP3 and ROS pharmacologic inhibitors, neutrophil necroptosis assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific conditional KO with defined TLR4/NF-κB pathway mechanism, pharmacologic rescue, and multiple readouts; single lab\",\n      \"pmids\": [\"38330550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tim-3 suppresses MHC-II expression in macrophages via the STAT1/CIITA pathway, thereby inhibiting MHC-II-mediated autoantigen presentation and CD4+ T cell activation. Overexpression or blockade of Tim-3 signaling altered MHC-II expression and clinical outcomes in EAE mice.\",\n      \"method\": \"Tim-3 overexpression/blockade in EAE mouse model, STAT1/CIITA pathway analysis, MHC-II expression assays, CD4+ T cell activation assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — defined STAT1/CIITA pathway mechanism with in vivo gain- and loss-of-function and functional antigen presentation readout; single lab\",\n      \"pmids\": [\"35095844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tim-3 suppresses Th17-mediated autoimmune hepatitis through the p38/MKP-1 pathway; blocking Tim-3 increased Th17 cell frequency and p38/MKP-1 and p-JNK activation, elevating IL-17A and liver damage.\",\n      \"method\": \"Anti-Tim-3 blockade in Con A-induced mouse AIH model, p38 inhibitor experiments, MKP-1 and IL-17A quantification, liver histology/enzyme assays\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway defined by pharmacologic inhibition and antibody blockade alone, single lab, no direct biochemical mechanism linking TIM-3 to p38/MKP-1\",\n      \"pmids\": [\"33728805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"T-bet transcription factor, induced in monocyte/macrophages by HCV core protein via gC1qR interaction and the JNK signaling pathway, drives Tim-3 expression; silencing T-bet decreases Tim-3 expression, enhances IL-12 secretion and STAT1 phosphorylation in macrophages.\",\n      \"method\": \"T-bet knockdown, HCV core protein stimulation of primary macrophages and THP-1 cells, JNK inhibitor (SP600125), T-bet/Tim-3 correlation analysis, IL-12/STAT1 phosphorylation assays\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — T-bet identified as upstream transcriptional regulator of TIM-3 using siRNA knockdown plus pathway inhibitor with downstream functional readouts; single lab\",\n      \"pmids\": [\"27809352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NEGATIVE FINDING: TIM-3 and CEACAM1 do not interact in cis or in trans. Extensive binding studies found no evidence of direct TIM-3–CEACAM1 interaction, and CEACAM1-mediated inhibition did not involve TIM-3. However, cytoplasmic sequences derived from TIM-3 independently induced inhibitory signaling in a human T cell reporter system.\",\n      \"method\": \"T cell reporter assay platform, extensive binding studies (cis and trans configurations), T cell co-expression analysis, cytoplasmic domain signaling assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays and reporter systems, single lab; clearly negative interaction result combined with positive finding that TIM-3 cytoplasmic domain drives inhibitory signaling independently\",\n      \"pmids\": [\"32222966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Among TIM-3 ligands tested on NK cells, galectin-9 most consistently suppresses NK cell-mediated cytotoxicity and proliferation through TIM-3 signaling, while also promoting IFN-γ release in a TIM-3-dependent manner. Galectin-9-mediated suppression of proliferation also occurred through CD44 signaling (independent of TIM-3).\",\n      \"method\": \"In vitro NK cell killing, proliferation, and cytokine production assays with four TIM-3 ligands (galectin-9, PtdSer, HMGB1, CEACAM1), TIM-3-blocking antibodies, HNSCC patient NK cell studies, flow cytometry\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple ligands compared in functional assays with receptor-blocking controls, patient samples included; single lab\",\n      \"pmids\": [\"39773563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TIM-3 expression in Jurkat T cells is associated with decreased glucose uptake and consumption, reduced lactate release, and decreased Glut1 (but not Glut2/3/4) expression, indicating TIM-3 suppresses T cell glycolysis.\",\n      \"method\": \"TIM-3 overexpression and knockout in Jurkat T cells, glucose uptake/consumption assays, lactate release measurement, glucose transporter expression analysis\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single cell line model with overexpression and KO, correlation of TIM-3 with metabolic readouts without defined signaling mechanism; single lab\",\n      \"pmids\": [\"32819283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Inhibition of melanoma cell-intrinsic TIM-3 promotes tumor growth via enhanced phosphorylation of MAPK signaling mediators (pro-proliferative). Melanoma-specific TIM-3 overexpression attenuated tumorigenesis in both immunocompetent and immunocompromised mice. Pharmacologic MAPK inhibition reversed TIM-3-antibody-mediated tumor growth promotion.\",\n      \"method\": \"Melanoma-specific TIM-3 knockdown and overexpression in vivo (immunocompetent and T-cell-deficient mice), MAPK phosphorylation assays, MEK inhibitor combination experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined MAPK pathway mechanism, multiple mouse models, pharmacologic rescue; single lab\",\n      \"pmids\": [\"35980306\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIM-3 (HAVCR2) is a type I transmembrane immune checkpoint receptor with multiple ligands (galectin-9, phosphatidylserine, HMGB1) that exerts context-dependent co-inhibitory or co-stimulatory functions across immune cell types: on T cells it engages PS to promote NF-κB/IL-2 signaling acutely but drives exhaustion chronically; on dendritic cells it suppresses ROS/NLRP3 inflammasome activation and IL-1β/IL-18 production to restrain anti-tumor immunity; on NK cells it inhibits PI3K/Akt/mTORC1 signaling (via competition for the p85 subunit) to dampen cytotoxicity; it regulates microglial homeostasis by interacting with SMAD2/TGFBR2 to enhance TGFβ signaling; its surface stability is controlled by DHHC9-mediated palmitoylation at Cys296, which prevents HRD1-mediated ubiquitination and degradation; and its adaptor protein Bat3 binds its cytoplasmic tail to modulate DC steroidogenesis and T cell priming.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HAVCR2 (TIM-3) is a type I transmembrane immune receptor that exerts context-dependent co-stimulatory and co-inhibitory control across immune and non-immune cell types through multiple ligands and intracellular adaptors [#0, #6, #4]. Several ligands engage its IgV domain: galectin-9 binding triggers calcium flux and selective death of TH1 cells [#0] and suppresses NK cytotoxicity and proliferation [#20]; phosphatidylserine engagement drives TCR-proximal NF-\\u03baB signaling and IL-2 secretion in T cells [#6] but on NK cells promotes TIM-3 phosphorylation that lets it compete with PI3K p110 for the p85 regulatory subunit, suppressing Akt/mTORC1 signaling and cytotoxicity [#4]; and HMGB1 binding inhibits NF-\\u03baB in CD4+ T cells during sepsis [#12]. On dendritic cells TIM-3 restrains anti-tumor immunity by preventing ROS-driven NLRP3 inflammasome activation and IL-1\\u03b2/IL-18 production [#5], and mediates phosphatidylserine-dependent trogocytosis of CD8+ T cells [#8]; its cytoplasmic-tail adaptor Bat3 limits DC steroidogenesis and the unfolded protein response to preserve effector T cell responses [#9]. In microglia, TGF\\u03b2-induced TIM-3 interacts with SMAD2 and TGFBR2 through its C-terminal tail to enhance SMAD2 phosphorylation and maintain homeostasis, restraining a neurodegenerative phenotype [#11]. Surface abundance is set post-translationally: DHHC9-mediated palmitoylation at Cys296 blocks HRD1-dependent ubiquitination and degradation, stabilizing the receptor and promoting exhaustion [#10]. Germline missense mutations (p.Tyr82Cys, p.Ile97Met) that misfold the protein and abolish surface expression cause hemophagocytic lymphohistiocytosis and subcutaneous panniculitis-like T-cell lymphoma through persistent immune activation and TNF-\\u03b1/IL-1\\u03b2 hypersecretion [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing the first functional ligand answered how TIM-3 transmits a regulatory signal, defining galectin-9 as a ligand that eliminates TH1 cells and suppresses autoimmunity.\",\n      \"evidence\": \"Calcium flux, cell aggregation/death assays in Tim-3+ T cells and in vivo galectin-9 administration in mouse autoimmunity\",\n      \"pmids\": [\"16286920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the binding interface or downstream signaling biochemistry\", \"Human-system relevance later contested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A negative report challenged the galectin-9 model by failing to detect specific binding to human or murine TIM-3, raising the question of which ligand drives human T cell function.\",\n      \"evidence\": \"Binding studies and T cell activation assays in human and murine systems plus HIV patient T cell assays\",\n      \"pmids\": [\"23555261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Negative binding result does not exclude low-affinity or context-dependent interaction\", \"Single-lab discrepancy with prior in vivo data\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying a co-stimulatory role in mast cells showed TIM-3 is not exclusively inhibitory, augmenting Fc\\u03b5RI-proximal Lyn-dependent signaling.\",\n      \"evidence\": \"Gain- and loss-of-function in mast cells with Lyn pathway, degranulation and cytokine readouts\",\n      \"pmids\": [\"26598760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ligand driving mast cell signaling not defined\", \"Cytoplasmic motifs mediating Lyn engagement not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Germline loss-of-function mutations established TIM-3 as a causal restraint on inflammation in humans, linking surface loss to hyperinflammatory disease.\",\n      \"evidence\": \"Sequencing, surface-expression analysis and cytokine quantification in HLH/SPTCL patients with cell models\",\n      \"pmids\": [\"30374066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type responsible for the inflammatory phenotype not pinpointed\", \"Mechanism connecting misfolding to cytokine hypersecretion not fully defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defining the NK-cell mechanism showed how PS engagement converts TIM-3 into an inhibitor of metabolic-cytotoxic signaling by competing for PI3K p85.\",\n      \"evidence\": \"Phosphorylation and competitive p85-binding assays, Akt/mTORC1 analysis, NK functional assays and in vivo HCC model\",\n      \"pmids\": [\"31848194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation residues mediating p85 competition not enumerated\", \"Generality beyond NK cells unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reconciling co-stimulatory vs co-inhibitory roles, PS-binding-site mutagenesis showed PS engagement in T cells promotes NF-\\u03baB/IL-2 and alters CD28 phosphorylation, defining a context-dependent acute signal.\",\n      \"evidence\": \"PS-binding-site mutagenesis, NF-\\u03baB reporter, IL-2 ELISA, CD28 phosphorylation and antibody blockade in Jurkat cells\",\n      \"pmids\": [\"34435619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the same PS ligand yields opposite outcomes across cell types not mechanistically unified\", \"Endogenous T cell validation beyond Jurkat needed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Cell-type-specific knockouts revealed the dominant anti-tumor checkpoint function resides in dendritic cells, where TIM-3 suppresses the NLRP3 inflammasome.\",\n      \"evidence\": \"Conditional DC/CD4/CD8 KO with genetic epistasis, scRNA-seq, ROS and inflammasome assays, IL-1\\u03b2/IL-18 blockade and tumor models\",\n      \"pmids\": [\"34108686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link from TIM-3 to ROS/NLRP3 suppression not biochemically defined\", \"Ligand driving DC-intrinsic signal not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"TIM-3 was shown to act intracellularly in macrophages, targeting the viral sensor NF90 for TRIM47-mediated K48 ubiquitination to suppress antiviral innate immunity.\",\n      \"evidence\": \"Co-IP, K48 ubiquitination and domain-mapping assays, Tim-3 inactivation, stress-granule and eIF2\\u03b1/PKR readouts and in vivo VSV challenge\",\n      \"pmids\": [\"34110282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a surface receptor accesses cytoplasmic NF90 not resolved\", \"Relationship to canonical ligand-driven signaling unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"HMGB1 was identified as a TIM-3 ligand inhibiting NF-\\u03baB in CD4+ T cells, contributing to sepsis-induced immunosuppression.\",\n      \"evidence\": \"Colocalization of HMGB1 and TIM-3, NF-\\u03baB analysis, conditional Tim-3 deletion and sepsis mortality model\",\n      \"pmids\": [\"34933101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction based on colocalization rather than direct biochemical binding\", \"Binding interface unmapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"The Bat3 adaptor was defined as an endogenous regulator of the TIM-3 tail, controlling DC steroidogenesis and the UPR to shape T cell quality.\",\n      \"evidence\": \"Bat3 conditional DC deletion, EAE and MC38-OVA models, steroidogenesis and acetyl-CoA assays, T cell phenotyping\",\n      \"pmids\": [\"35275752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct structural basis of Bat3 tail binding not detailed\", \"Whether ligand engagement modulates Bat3 release unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A trogocytosis mechanism explained how DC-intrinsic TIM-3 produces fratricide of tumor-reactive CD8+ T cells via PS-dependent membrane transfer.\",\n      \"evidence\": \"Human melanoma TIL analysis, PS-blocking, DC-specific conditional KO and two melanoma models with trogocytosis/fratricide assays\",\n      \"pmids\": [\"35316223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery executing membrane transfer downstream of TIM-3 not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Tumor-cell-intrinsic TIM-3 roles were defined: in glioblastoma it drives NF-\\u03baB/IL-6 to polarize macrophages, and in melanoma it restrains pro-proliferative MAPK signaling.\",\n      \"evidence\": \"Gain/loss-of-function in glioma and melanoma cells, NF-\\u03baB/IL-6 and MAPK pathway analyses, macrophage co-culture and in vivo pharmacologic rescue\",\n      \"pmids\": [\"36325060\", \"35980306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cancer-cell-intrinsic ligands and proximal signaling steps undefined\", \"Single-lab findings per tumor type\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Post-translational control of receptor abundance was established: DHHC9-mediated Cys296 palmitoylation blocks HRD1 binding and degradation, a node exploitable to reduce exhaustion.\",\n      \"evidence\": \"Palmitoylation and Cys296 mutagenesis, Co-IP with HRD1, ubiquitination assays, DHHC9 knockdown, CAR-T exhaustion and peptidic inhibitor experiments\",\n      \"pmids\": [\"39546589\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether palmitoylation status is signal-regulated in vivo unclear\", \"Stoichiometry with HRD1 vs other ligases not resolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Comparative ligand testing on NK cells re-affirmed galectin-9 as the most consistent suppressive ligand while revealing TIM-3-independent CD44 signaling.\",\n      \"evidence\": \"NK killing, proliferation and cytokine assays with four ligands, TIM-3-blocking antibodies and HNSCC patient NK cells\",\n      \"pmids\": [\"39773563\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative ligand affinities and binding sites not biochemically ranked\", \"Single-lab functional comparison\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A non-immune homeostatic role was defined: TGF\\u03b2-induced microglial TIM-3 binds SMAD2/TGFBR2 to amplify SMAD2 phosphorylation, restraining a neurodegenerative microglial phenotype.\",\n      \"evidence\": \"Co-IP (TIM-3 with SMAD2 and TGFBR2), SMAD2 phosphorylation assays, microglia-specific Havcr2 KO, 5xFAD model and sc/snRNA-seq\",\n      \"pmids\": [\"40205047\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of TIM-3 tail engagement with SMAD2/TGFBR2 not resolved\", \"Whether ligand binding gates this interaction unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unifying biochemical model for how a single cytoplasmic tail toggles between activating (NF-\\u03baB/IL-2), inhibitory (PI3K competition), degradative (NF90/TRIM47), and adaptor/scaffold (Bat3, SMAD2/TGFBR2) functions across cell types remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structure of the signaling-competent tail with its partners\", \"Ligand-specific signaling outputs not mechanistically separated\", \"Conflicting galectin-9 binding data across human/murine systems unreconciled\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [4, 6, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 9, 11]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [9, 11]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 5, 8]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 6, 11]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LGALS9\", \"PIK3R1\", \"BAG6\", \"ZBTB32\", \"SMAD2\", \"TGFBR2\", \"SYVN1\", \"ZDHHC9\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}